China NMPA Drug Inspection - Shaanxi Ziguang Chenji Pharmaceutical Co., Ltd. - Huanglian Shangqing Pills

On November 19, 2019, the Chongqing Municipal Drug Administration announced that four batches of drugs from four distinct manufacturers failed to meet established quality standards following testing by local drug inspection institutes. Shenyang Shenlong Pharmaceutical Co., Ltd.'s Qianlielongbitong Tablets (batch 20180602) were found non-compliant in both appearance and general inspection parameters. Harbin Sanmu Pharmaceutical Factory's Qiangli Zhike Ning Capsules (batch JN190201) and Hengtuo Group Guangxi Shengkang Pharmaceutical Co., Ltd.'s Laoren Kechuan Capsules (batch 180304) both failed general inspection requirements. Similarly, Shaanxi Ziguang Chenji Pharmaceutical Co., Ltd.'s Huanglian Shangqing Pills (batch 817035) also failed general inspection. These violations indicate potential issues with the drugs' quality characteristics, safety, efficacy, or manufacturing uniformity, as evaluated against national drug standards including the Chinese Pharmacopoeia. In response, the Chongqing Municipal Drug Administration mandated immediate control measures. These required actions included sealing, seizing, suspending sales, and recalling the affected drug batches, with further processing to be conducted in accordance with relevant laws and regulations to safeguard public health.